1. Scrip
  2. >>Therapy Areas

Novartis Eyes Fourth Approval For Cosentyx

An nr-axSpA okay will boost Swiss major's biggest seller

 
• By Kevin Grogan

As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.

Four
Cosentyx could soon be approved for four indications • Source: Shutterstock

The steep revenue rise Novartis AG has been enjoying with Cosentyx is set to continue with the Swiss major filing for a fourth indication, non-radiographic axial spondyloarthritis (nr-axSpA).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

 
• By Joseph Haas

CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.